表紙:多発性硬化症治療薬の世界市場(2022年)
市場調査レポート
商品コード
1062914

多発性硬化症治療薬の世界市場(2022年)

Multiple Sclerosis Drugs Global Market Report 2022

出版日: 受注後作成 | 発行: The Business Research Company | ページ情報: 英文 400 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=130.29円
多発性硬化症治療薬の世界市場(2022年)
出版日: 受注後作成
発行: The Business Research Company
ページ情報: 英文 400 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の多発性硬化症治療薬市場について調査し、市場規模や予測、市場力学、セグメント・地域別の市場分析、競合情勢、戦略、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 多発性硬化症治療薬市場の特徴

第3章 多発性硬化症治療薬の市場動向と戦略

第4章 多発性硬化症治療薬に対するCOVID-19の影響

第5章 多発性硬化症治療薬の市場規模と成長

  • 市場実績(金額)
    • 市場促進要因
    • 市場抑制要因
  • 市場予測(金額)
    • 市場促進要因
    • 市場抑制要因

第6章 多発性硬化症治療薬市場のセグメンテーション

  • 市場実績と予測(金額):医薬品クラス別
  • 免疫調節剤
  • 免疫抑制剤
  • インターフェロン
  • その他
  • 市場実績と予測(金額):流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンラインストア
  • 市場実績と予測(金額):投与経路別
  • 経口薬
  • 非経口薬

第7章 多発性硬化症治療薬市場の地域・国分析

  • 市場実績と予測(金額):地域別
  • 市場実績と予測(金額):国別

第8章 アジア太平洋地域の多発性硬化症治療薬市場

  • 市場概要
  • 地域情報、COVID-19の影響、市場情報、背景情報、政府のイニシアチブ、規制、規制機関、主要な協会、徴収される税金、法人税の構造、投資、主要企業
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第9章 中国の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第10章 インドの多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第11章 日本の多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第12章 オーストラリアの多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第13章 インドネシアの多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第14章 韓国の多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第15章 西欧の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第16章 英国の多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第17章 ドイツの多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第18章 フランスの多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第19章 東欧の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第20章 ロシアの多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第21章 北米の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第22章 米国の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第23章 南米の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第24章 ブラジルの多発性硬化症治療薬市場

  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第25章 中東の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第26章 アフリカの多発性硬化症治療薬市場

  • 市場概要
  • 市場実績と予測(金額):医薬品クラス別
  • 市場実績と予測(金額):流通チャネル別

第27章 多発性硬化症治療薬市場の競合情勢と企業プロファイル

  • 多発性硬化症治療薬市場の競合情勢
  • 多発性硬化症治療薬市場の企業プロファイル
    • Biogen
    • Novartis
    • Roche
    • Bayer HealthCare
    • Pfizer, Inc.

第28章 多発性硬化症治療薬のパイプライン分析

第29章 多発性硬化症治療薬市場における主な合併と買収

第30章 多発性硬化症治療薬市場の将来展望と潜在的分析

第31章 付録

目次
Product Code: h1136

“Multiple Sclerosis Drugs Global Market Report 2022” from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global multiple sclerosis drugs market.

This report focuses on multiple sclerosis market which is experiencing strong growth. The report gives a guide to the multiple sclerosis market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the multiple sclerosis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The Multiple Sclerosis Drugs market global report” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider multiple sclerosis drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The multiple sclerosis drugs market section of the report gives context. It compares the multiple sclerosis drugs market with other segments of the multiple sclerosis drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, multiple sclerosis drugs indicators comparison.

Scope

Markets Covered:

1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others

2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores

3) By Route Of Administration: Oral Drugs; Parenteral Drugs

Companies Mentioned: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer, Inc.

Countries: Brazil; China; France; Germany; India; Indonesia; Japan; South Korea; Russia; UK; USA; Australia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Executive Summary

2. Multiple Sclerosis Drugs Market Characteristics

3. Multiple Sclerosis Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Multiple Sclerosis Drugs

5. Multiple Sclerosis Drugs Market Size And Growth

  • 5.1. Global Multiple Sclerosis Drugs Historic Market, 2016-2021, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Multiple Sclerosis Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Multiple Sclerosis Drugs Market Segmentation

  • 6.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others
  • 6.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • 6.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oral Drugs
  • Parenteral Drugs

7. Multiple Sclerosis Drugs Market Regional And Country Analysis

  • 7.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 7.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Multiple Sclerosis Drugs Market

  • 8.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 8.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Multiple Sclerosis Drugs Market

  • 9.1. China Multiple Sclerosis Drugs Market Overview
  • 9.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
  • 9.3. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Multiple Sclerosis Drugs Market

  • 10.1. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 10.2. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Multiple Sclerosis Drugs Market

  • 11.1. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 11.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Multiple Sclerosis Drugs Market

  • 12.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 12.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Multiple Sclerosis Drugs Market

  • 13.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 13.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Multiple Sclerosis Drugs Market

  • 14.1. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 14.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Multiple Sclerosis Drugs Market

  • 15.1. Western Europe Multiple Sclerosis Drugs Market Overview
  • 15.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 15.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Multiple Sclerosis Drugs Market

  • 16.1. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 16.2. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Multiple Sclerosis Drugs Market

  • 17.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 17.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Multiple Sclerosis Drugs Market

  • 18.4. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 18.5. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Multiple Sclerosis Drugs Market

  • 19.1. Eastern Europe Multiple Sclerosis Drugs Market Overview
  • 19.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 19.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Multiple Sclerosis Drugs Market

  • 20.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 20.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Multiple Sclerosis Drugs Market

  • 21.1. North America Multiple Sclerosis Drugs Market Overview
  • 21.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 21.3. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Multiple Sclerosis Drugs Market

  • 22.1. USA Multiple Sclerosis Drugs Market Overview
  • 22.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 22.3. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Multiple Sclerosis Drugs Market

  • 23.1. South America Multiple Sclerosis Drugs Market Overview
  • 23.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 23.3. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Multiple Sclerosis Drugs Market

  • 24.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 24.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Multiple Sclerosis Drugs Market

  • 25.1. Middle East Multiple Sclerosis Drugs Market Overview
  • 25.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 25.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

26. Africa Multiple Sclerosis Drugs Market

  • 26.1. Africa Multiple Sclerosis Drugs Market Overview
  • 26.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 26.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

27. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

  • 27.1. Multiple Sclerosis Drugs Market Competitive Landscape
  • 27.2. Multiple Sclerosis Drugs Market Company Profiles
    • 27.2.1. Biogen
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Novartis
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Roche
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Bayer HealthCare
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Pfizer, Inc.
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Multiple Sclerosis Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

30. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Research Inquiries
  • 31.4. The Business Research Company
  • 31.5. Copyright And Disclaimer